Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma

The cost per MRD-negative patient and the cost per patient achieving sustained MRD negativity during maintenance were lower with DVRd/DR compared with VRd/R. These findings demonstrate the cost savings associated with the use of DVRd induction/consolidation followed by DR maintenance for transplant-eligible patients with newly diagnosed multiple myeloma, supplementing the superior efficacy benefits relative to VRd induction/consolidation demonstrated in the PERSEUS trial.